Frequency of New-Onset Pathologic Compulsive Gambling or Hypersexuality After Drug Treatment of Idiopathic Parkinson Disease

Michael^Bostwick, J.; Hecksel, Kathleen A.; Stevens, Susanna R.; Bower, James H.; Ahlskog, J. Eric
April 2009
Mayo Clinic Proceedings;Apr2009, Vol. 84 Issue 4, p310
Academic Journal
OBJECTIVE: To determine the frequency of new-onset compulsive gambling or hypersexuality among regional patients with Parkinson disease (PD), ascertaining the relationship of these behaviors to PD drug use. PATIENTS AND METHODS: We retrospectively reviewed the medical records of patients from 7 rural southeastern Minnesota counties who had at least 1 neurology appointment for PD between July 1, 2004, and June 30, 2006. The main outcome measure was compulsive gambling or hypersexuality developing after parkinsonism onset, including the temporal relationship to PD drug use. RESULTS: Of 267 patients with PD who met the study inclusion criteria, new-onset gambling or hypersexuality was documented in 7 (2.6%). All were among the 66 patients (10.6%) taking a dopamine agonist. Moreover, all 7 (18.4%) were among 38 patients taking therapeutic doses (defined as ⩾2 mg of pramipexole or 6 mg of ropinirole daily). Behaviors were clearly pathologic and disabling in 5: 7.6% of all patients taking an agonist and 13.2% of those taking therapeutic doses. Of the 5 patients, 2 had extensive treatment for what was considered a primary psychiatric problem before the agonist connection was recognized. CONCLUSION: Among the study patients with PD, new-onset compulsive gambling or hypersexuality was documented in 7 (18.4%) of 38 patients taking therapeutic doses of dopamine agonists but was not found among untreated patients, those taking subtherapeutic agonist doses, or those taking carbldopa/levodopa alone. Behaviors abated with discontinuation of agonist therapy or dose reduction. Because this is a retrospective study, cases may have been missed, and hence this study may reflect an underestimation of the true frequency. Physicians who care for patients taking these drugs should recognize the drug's potential to induce pathologic syndromes that sometimes masquerade as primary psychiatric disease.


Related Articles

  • Dopamine agonists and therapy compliance. Grosset, Donald // Neurological Sciences;Dec2008 Supplement 5, Vol. 29, p375 

    Dopamine replacement therapy in Parkinson’s disease improves motor symptoms, however some patients suffer from motor and behavioural disturbances attributable to taking doses of medication well beyond the dose required to treat their motor disabilities. Dopamine dysregulation syndrome...

  • Comparison of patient rated treatment response with measured improvement in Parkinson's disease. Davidson, Matthew B.; McGhee, David J. M.; Counsell, Carl E. // Journal of Neurology, Neurosurgery & Psychiatry;Oct2012, Vol. 83 Issue 10, p1001 

    Background A marked response to dopamine replacement therapy is important in supporting a diagnosis of idiopathic Parkinson's disease (PD). The aim of the study was to compare PD patients' subjective rating of improvement with measured improvement on a number of scales. Methods People with...

  • Factores asociados con la selección de pramipexol de liberación prolongada versus liberación inmediata en pacientes con enfermedad de Parkinson. Cervantes-Arriaga, Amin; Rodríguez-Violante, Mayela; López-Ruiz, Minerva; Estrada-Bellmann, Ingrid; Zúñiga-Ramírez, Carlos; Otero-Cerdeira, Elisa; Camacho-Ordóñez, Azyadeh; González-Latapi, Paulina; Morales-Briceño, Hugo; Martínez-Ramírez, Daniel // Revista Mexicana de Neurociencia;Mar/Apr2013, Vol. 14 Issue 2, p76 

    Introduction: Pramipexole is a dopamine agonist effective to treat the motor symptoms of Parkinson disease available as immediate or extended release. Objective: The aim of this study is to determine whether there are differences in the profile of patients receiving pramipexole according to the...

  • WHEN INITIAL TREATMENT BEGINS TO FAIL…. Mari, Zoltan // Johns Hopkins Advanced Studies in Medicine;12/10/2008, Vol. 8 Issue 12, p423 

    Most clinicians today consider dopamine agonist therapy as the treatment of choice for initial therapy in young patients with Parkinson's disease (PD), where such medications are tolerated and not otherwise contraindicated. However, as PD progresses, limitations to agonist therapy are often...

  • Parkinson's treatment may increase risk of heart disorder.  // Geriatrics;Mar2007, Vol. 62 Issue 3, p15 

    The article provides information on the results of two studies on the risk of having heart valve regurgitation in using dopamine agonists pergolide and cabergoline to treat Parkinson's disease. The "Dopamine Agonists and the Risk of Cardiac-Valve Regurgitation," conducted by physician Rene...

  • Management of Parkinson disease: Current treatments, recent advances, and future development. Lo, Keras; Leung, Kevin; Shek, Allen // Formulary;Sep2007, Vol. 42 Issue 9, p529 

    Parkinson disease (PD) is a chronic progressive neurodegenerative disorder that affects >1 million people in the United States. PD causes both motor and nonmotor disturbances; common symptoms include resting tremor, rigidity, and bradykinesia. The current goals of treatment are to slow disease...

  • pergolide.  // Davis's Drug Guide for Nurses, 10th edition;2007, p941 

    The article presents information on the drug pergolide for nurses. This drug treats Parkinson's disease. As dopamine agonist, it is well absorbed following oral administration. Patients who take this drug would experience continued relief of symptoms of Parkinson's disease at a lower dose of...

  • Sleep attacks in patients taking dopamine agonists: review. Homann, Carl Nikolaus; Wenzel, Karoline; Suppan, Klaudia; Ivanic, Gerd; Kriechbaum, Norbert; Crevenna, Richard; Ott, Erwin // BMJ: British Medical Journal (International Edition);6/22/2002, Vol. 324 Issue 7352, p1483 

    Abstract Objectives: To assess the evidence for the existence and prevalence of sleep attacks in patients taking dopamine agonists for Parkinson's disease, the type of drugs implicated, and strategies for prevention and treatment. Design: Review of publications between July 1999 and May 2001 in...

  • Levodopa-induced dyskinesia in Parkinson's disease: clinical features, pathogenesis, prevention and treatment. Thanvi, Bhomraj; Lo, Nelson; Robinson, Tom // Postgraduate Medical Journal;Jun2007, Vol. 83 Issue 980, p384 

    Levodopa is the most effective drug for treating Parkinson's disease. However, long-term use of levodopa is often complicated by significantly disabling fluctuations and dyskinesias negating its beneficial effects. Younger age of Parkinson's disease onset, disease severity, and high levodopa...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics